Optical mammography improves with Tufts University near-IR technique

Medford, MA--Tufts University has developed new NIR imaging technology that can both identify breast cancer and monitor patient response to treatment.

An optical mammography image shows hemoglobin oxygenation of a duct carcinoma in situ (DCIS)--a breast cancer in the lining of the milk ducts that has not yet invaded nearby tissues. The boxed area corresponds to the cancer location and indicates lower values of hemoglobin oxygenation. For cancerous tissue that is associated with abnormal hemoglobin concentration and oxygenation, optical mammography can be used to help diagnose breast cancer and also indicate how well a patient responds to breast cancer chemotherapy. (Courtesy Tufts University)
An optical mammography image shows hemoglobin oxygenation of a duct carcinoma in situ (DCIS)--a breast cancer in the lining of the milk ducts that has not yet invaded nearby tissues. The boxed area corresponds to the cancer location and indicates lower values of hemoglobin oxygenation. For cancerous tissue that is associated with abnormal hemoglobin concentration and oxygenation, optical mammography can be used to help diagnose breast cancer and also indicate how well a patient responds to breast cancer chemotherapy. (Courtesy Tufts University)

Medford, MA--Tufts University School of Engineering has developed new near-infrared (near-IR or NIR) imaging technology that could give doctors new ways to both identify breast cancer and monitor individual patients' response to initial treatment of the disease, thanks to a five-year clinical study funded by a $3.5 million grant from the National Institutes of Health that is now underway at Tufts Medical Center in Boston. The non-invasive, non-x-ray technology uses NIR light to scan breast tissue and then applies an algorithm that interprets the differences in light absorption seen for water, fats, and oxygen-rich and oxygen-poor tissue--the primary structures in breast tissue.

"The consensus is that x-ray mammography is very good at detecting lesions but it's not as good at determining which suspicious lesions are really cancer," says professor of Biomedical Engineering Sergio Fantini, who is leading the research effort. The Tufts NIR technique could complement standard mammography, particularly for women younger than 40 who may have dense breast tissue that tends to obscure detail in x-ray images. Because it does not use ionizing radiation, the noninvasive NIR technique can be applied multiple times over a short period without risk of radiation exposure. And unlike other breast imaging methods, it can obtain functional real-time images of metabolic changes, such as levels of hemoglobin concentration and oxygenation.

"It's been reported that patients who respond to breast cancer chemotherapy show a decrease in hemoglobin and water concentration and an increase in lipid concentration at the cancer site," explains Fantini. "This suggests that NIR imaging can be valuable not only in diagnosing breast cancer but in monitoring individual response to therapies without requiring repeated x-rays. For example, it could help determine if a patient is responding to neoadjuvant chemotherapy administered to shrink a tumor before surgery." Optical mammography is also more comfortable than traditional mammograms. The patient's breasts are only lightly compressed between two horizontal glass panels and then illuminated by NIR light. A specialized software program displays real-time images of the breast as the optical system scans back and forth. A light detector within the system displays the intensity of the NIR beam as it is transmitted through the breast.

By using an algorithm based on the optical information, the technology generates breast images using the intensity of the transmitted light. The images are displayed automatically and can be read soon after the procedure, as is the case with x-ray mammograms. The technology can be packaged into compact, portable and handheld devices.

In collaboration with Roger Graham, MD, director of Tufts Medical Center's Breast Health Center, and Marc Homer, MD, chief of mammography at Tufts Medical Center, Fantini and his team conducted "proof of concept" tests to see if their procedure could corroborate information gathered with x-rays on two patients who each had suspicious lesions in one of their breasts. The optical imaging was successful in enabling the team to identify cancerous tissue.

The NIH-funded study will investigate healthy women, women with breast cancer and women with benign breast lesions in an effort to examine the effectiveness of optical mammography in detecting breast cancer and distinguishing between malignant and benign tumors. The study will also look at breast cancer patients who are undergoing chemotherapy in order to characterize the power of optical mammography to determine patient response at the beginning of therapeutic treatment.

Fantini and his colleagues have published numerous papers on optical mammography at http://ase.tufts.edu/biomedical/research/fantini/publications/opticalMammography.asp.

SOURCE: Tufts University; http://now.tufts.edu/news-releases/optical-mammography-sheds-new-light-breast-ca

IMAGE: An optical mammography image shows hemoglobin oxygenation of a duct carcinoma in situ (DCIS)--a breast cancer in the lining of the milk ducts that has not yet invaded nearby tissues. The boxed area corresponds to the cancer location and indicates lower values of hemoglobin oxygenation. For cancerous tissue that is associated with abnormal hemoglobin concentration and oxygenation, optical mammography can be used to help diagnose breast cancer and also indicate how well a patient responds to breast cancer chemotherapy. (Courtesy Tufts University)

More in Software